



Core Project R03OD030604



Details







Projects	Name	Award	Publications	Repositories	Analytics
1R03OD030604-01	Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing	\$297,000.00	9 publications	0 repositories	0 properties













Publications

Published works associated with this project.

ID	Title	Authors	R C R	SJ R	Cita tion s	Cit./ yea r	Journal	Publ ishe d	Updat ed
35337371 DOI	Considerations and challenges for sex-aware drug repurposing.	Jennifer L Fisher	1. 41	0	9	4.5	Biol Sex Differ	2022	Dec 1, 2024

		...4 more... Brittany N Lasseign e							(3 weeks ago)
37533331  DOI 	Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease...	Avery S Williams ...2 more... Brittany N Lasseign e	0. 96	0	3	3	Cancer Rep (Hoboken)	2023	Dec 1, 2024 (3 weeks ago)
36602970  DOI 	Ten simple rules for using public biological data for your research.	Vishal H Oza ...9 more... Brittany N Lasseign e	0. 56	0	2	2	PLoS Comput Biol	2023	Dec 1, 2024 (3 weeks ago)
37824797  DOI 	Computational Advancements in Cancer Combination Therapy Prediction.	Victoria L Flanary ...3 more... Brittany	0. 43	0	2	2	JCO Precis Oncol	2023	Dec 1, 2024 (3 weeks ago)

		N Lasseign e								
37217845  DOI 	Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and...	Elizabeth J Wilk ...9 more... Brittany N Lasseign e	0.36	0	1	1	Mol Med	2023	Dec 1, 2024 (3 weeks ago)	
37090499  DOI 	Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease...	Avery S Williams ...2 more... Brittany N Lasseign e	0	0	0	0	bioRxiv	2023	Dec 1, 2024 (3 weeks ago)	
37362157  DOI 	Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ...	Jennifer L Fisher ...2 more... Brittany N Lasseign e	0	0	0	0	bioRxiv	2023	Dec 1, 2024 (3 weeks ago)	

38531616  DOI 	Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposi...	Jennifer L Fisher ...7 more... Brittany N Lasseigne	0	0	0	0	FEBS Open Bio	2024	Dec 1, 2024 (3 weeks ago)
38167211  DOI 	Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ...	Jennifer L Fisher ...2 more... Brittany N Lasseigne	0	0	0	0	BMC Pharmacol Toxicol	2024	Dec 1, 2024 (3 weeks ago)

Notes

- RCR [Relative Citation Ratio](#) 
- SJR [Scimago Journal Rank](#) 

Publications (cumulative)
Total: 9



Name	Tags	Last Commit	Avg Issue	Avg PR	Languages	License	Readme	Contributing	Dependencies
No data									

Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the `main` /default branch is considered for metrics like # of commits.

of dependencies is totaled from all manifests in repo, direct and transitive, e.g. `package.json` + `package-lock.json`.

Analytics

Traffic metrics of websites associated with this project.

Notes

Active Users [Distinct users who visited the website](#) .

New Users [Users who visited the website for the first time](#) .

Engaged Sessions [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.